Biological Assembly 1  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Biological Assembly 2  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 2 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 83.67 kDa 
• Atom Count: 5990 
• Modelled Residue Count: 669 
• Deposited Residue Count: 736 
• Unique protein chains: 1

2X7D

Crystal structure of human kinesin Eg5 in complex with (S)-dimethylenastron

• PDB DOI: 10.2210/pdb2X7D/pdb

• Classification: CELL CYCLE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2010-02-26 Released: 2010-07-14 
• Deposition Author(s): Kaan, H.Y.K., Ulaganathan, V., Rath, O., Laggner, C., Prokopcova, H., Dallinger, D., Kappe, C.O., Kozielski, F.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.30 Å
• R-Value Free: 0.241 
• R-Value Work: 0.176 
• R-Value Observed: 0.179 

Literature

Structural Basis for Inhibition of Eg5 by Dihydropyrimidines: Stereoselectivity of Antimitotic Inhibitors Enastron, Dimethylenastron and Fluorastrol.

Kaan, H.Y.K., Ulaganathan, V., Rath, O., Prokopcova, H., Dallinger, D., Kappe, C.O., Kozielski, F.

(2010) J Med Chem 53: 5676

• PubMed: 20597485 
• DOI: 10.1021/jm100421n
• Primary Citation of Related Structures:  
  2X7C, 2X7D, 2X7E


• PubMed Abstract: 
  

Human kinesin Eg5, which plays an essential role in mitosis by establishing the bipolar spindle, has proven to be an interesting drug target for the development of cancer chemotherapeutics. Here, we report the crystal structures of the Eg5 motor domain complexed with enastron, dimethylenastron, and fluorastrol. By comparing these structures to that of monastrol and mon-97, we identified the main reasons for increased potency of these new inhibitors, namely the better fit of the ligand to the allosteric binding site and the addition of fluorine atoms. We also noticed preferential binding of the S-enantiomer of enastron and dimethylenastron to Eg5, while the R-enantiomer of fluorastrol binds preferentially to Eg5. In addition, we performed a multidrug resistance (MDR) study in cell lines overexpressing P-glycoprotein (Pgp). We showed that one of these inhibitors may have the potential to overcome susceptibility to this efflux pump and hence overcome common resistance associated with tubulin-targeting drugs.

---

Organizational Affiliation: 

The Beatson Institute for Cancer Research, Garscube Estate, Bearsden, Glasgow, Scotland, UK.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
KINESIN-LIKE PROTEIN KIF11	A, B	368	Homo sapiens	Mutation(s): 0  Gene Names: KIF11, EG5, KNSL1, TRIP5
UniProt & NIH Common Fund Data Resources
Find proteins for P52732 (Homo sapiens) Explore P52732  Go to UniProtKB:  P52732
PHAROS:  P52732

Small Molecules

Ligands 3 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
ADP	C [auth A], G [auth B]	ADENOSINE-5'-DIPHOSPHATE C10 H15 N5 O10 P2 XTWYTFMLZFPYCI-KQYNXXCUSA-N
EGB	F [auth A], J [auth B]	(4S)-4-(3-HYDROXYPHENYL)-7,7-DIMETHYL-2-THIOXO-2,3,4,6,7,8-HEXAHYDROQUINAZOLIN-5(1H)-ONE C16 H18 N2 O2 S RUOOPLOUUAYNPY-AWEZNQCLSA-N
MG	D [auth A], E [auth A], H [auth B], I [auth B]	MAGNESIUM ION Mg JLVVSXFLKOJNIY-UHFFFAOYSA-N

Binding Affinity Annotations
ID	Source	Binding Affinity
EGB	PDBBind:  2X7D	IC50: 200 (nM) from 1 assay(s)
	Binding MOAD:  2X7D	IC50: 200 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.30 Å
• R-Value Free: 0.241 
• R-Value Work: 0.176 
• R-Value Observed: 0.179 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 69.515	α = 90
b = 79.717	β = 90
c = 159.277	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
iMOSFLM	data reduction
SCALA	data scaling
MOLREP	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2010-02-26 
• Released Date: 2010-07-14 
Deposition Author(s): Kaan, H.Y.K., Ulaganathan, V., Rath, O., Laggner, C., Prokopcova, H., Dallinger, D., Kappe, C.O., Kozielski, F.

Revision History  

• Version 1.0: 2010-07-14
  Type: Initial release
  
• Version 1.1: 2011-09-21
  Changes: Database references, Refinement description, Version format compliance